GTBP (GT Biopharma Inc) Cumulative Company Assets

Official company branding of GT Biopharma Inc (GTBP)

The market trend for GT Biopharma, Inc. (GTBP) on the GURU.Markets platform, as illustrated by this price chart, shows total assets at 9.58. GT Biopharma, Inc. (GTBP) relies on the innovative TriKE system, which provides significant pricing power by activating immune cells against tumors. The business remains independent of macroeconomic factors, evolving according to the stages of medical trials. Production capacities are functioning stably and are undergoing scheduled modernization to expand the output of biologics.

GT Biopharma Inc (GTBP) Aggregate Company Assets: for the period 07/04/2022 - 10/31/2026

Financial and market metric breakdowns for GT Biopharma Corp (GTBP)

- current price and projected stock value:
Quote Chart gtbiopharma.com|GTBP - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation GT Biopharma Corporation|GTBP - Enterprise Value
- company book value details:
Book Value per Share GT Biopharma|GTBP - Company Book Value|Capitalization to Book Value Ratio gtbiopharma.com|GTBP - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio GT Biopharma, Inc.|GTBP - Long-Term Debt to Capital|Current Liabilities to Capital GT Biopharma Corporation|GTBP - Company Debts|Debt to Net Assets Ratio GT Biopharma Corporation|GTBP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings GT Biopharma|Quick Liquidity gtbiopharma.com
- earnings and market multiples details:
GTBP - Company Net Income
Basic company analysis:gtbiopharma.com (GTBP)
Core merchandise of GT Biopharma

Since GT Biopharma, Inc. (GTBP) is in the early stages of clinical trials with high R&D expenditures, this balance sheet asset metric, calculated inversely via ROA, allows for the tracking of the company's actual resource dynamics stripped of market noise; steady growth of this indicator confirms the effective expansion of the foundation for future commercialization, while abnormal spikes may signal risky capital dilution.

Key competitors

Total Asset Value of Company TGTX (tgtherapeutics.com)|ACLX (Arcellx, Inc.) - Company Total Assets|Cumulative Company Assets Disc Medicine Inc (IRON)|Company Total Assets SNDX|Company Total Assets Kura (KURA)|Aggregate Company Assets ADC Therapeutics ADCT|FHTX: Total Business Assets|Vor Biopharma - Company Total Assets|Nkarta, Inc. (NKTX) - Cumulative Company Assets|COEP: Company Total Assets|Company Assets Actinium Corp (ATNM)|Aggregate Company Assets Estrella Immunopharma|CASI: Aggregate Asset Value|Cumulative Company Assets MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - Aggregate Asset Value|Company Total Assets ERNA (Eterna Therapeutics Inc.)|Aptose Biosciences Inc - Aggregate Company Assets|BPTH - Aggregate Company Assets|MEIP: Aggregate Company Assets|vincerx.com (VINC) - Aggregate Company Assets